Explore a selection of our essential drug information below, or:
Identification
- Brand Names
- Yf-vax
- Generic Name
- Yellow fever vaccine
- DrugBank Accession Number
- DB10805
- Background
Yellow fever vaccine prevents against Yellow Fever, a viral hemorrhagic disease caused by the transmission of a flavivirus through the bite of an infected mosquito. Symptoms of Yellow fever can range from asymptomatic, to mild flu-like illness, to more severe symptoms such as shock, jaundice, internal bleeding, and organ failure 4. Interestingly, Yellow fever got its name from the characteristic yellowing of the skin and eyes that occurs from the development of jaundice when the virus attacks the liver. Although there is supportive treatment available for managing Yellow Fever, there are currently no antivirals developed to specifically treat Yellow Fever. Vaccination with Yellow Fever vaccine is therefore considered to be the most important and effective measure to protect against Yellow Fever, with protective immunity developing within 10 days after vaccination; in two separate clinical trials of Yellow Fever Vaccine, 90% of subjects seroconverted within 10 days after vaccination, and 100% of subjects seroconverted within 14 days Label. The World Health Organization no longer recommends the use of a 10-year booster dose following primary immunization, as a single dose is "sufficient to confer life-long immunity against yellow fever disease" 3.
Yellow Fever is most commonly found in the southern hemisphere, in tropical regions of Africa and Central/South America 2. The World Health Organization recommends routine vaccination in countries where Yellow Fever is endemic, and for travellers going to endemic areas as proof of vaccination is often a requirement at border crossings to prevent international spread of the disease 2,5.
Yellow Fever Vaccine is a subcutaneously administered vaccination for the active immunization and prophylaxis of yellow fever in pediatric patients 9 months of age and older. It is composed of two live, attenuated strains of yellow fever virus, 17D-204 and 17DD, which have been shown to elicit an immune response identical to that induced by wild-type infection Label,1. The FDA recommends vaccination with Yellow Fever Vaccine for persons living in or travelling to endemic areas and for laboratory personnel who handle virulent yellow fever virus or concentrated preparations of the yellow fever vaccine virus.
- Type
- Biotech
- Groups
- Approved, Investigational
- Biologic Classification
- Vaccines
Attenuated - Synonyms
- Flavivirus yellow fever virus 17D-204 whole
- Yellow fever virus 17D/tiantan live antigen
- Yellow fever virus live antigen, A
- Yellow fever virus strain 17D (live, attenuated)
- Yellow fever virus strain 17D-204 live (attenuated) antigen
- Yellow fever virus strain 17D-204 live antigen
- Yellow fever, live attenuated
Pharmacology
- Indication
Yellow Fever Vaccine is indicated for active immunization for the prevention of yellow fever in persons 9 months of age and older in the following categories:
Persons Living in or Traveling to Endemic Areas: While the actual risk for contracting yellow fever during travel is probably low, variability of itineraries, behaviors and seasonal incidence of disease make it difficult to predict the actual risk for a given individual living in or traveling to a known endemic or epidemic area. Greater risk is associated with living in or traveling to areas of South America and Africa where yellow fever infection is officially reported at the time of travel and with traveling outside the urban areas of countries that do not officially report the disease but that lie in a yellow fever endemic zone.
Persons Travelling Internationally Through Countries with Yellow Fever: Some countries require an individual to have a valid International Certificate of Vaccination or Prophylaxis (ICVP) if the individual has been in countries either known or thought to harbor yellow fever virus. The certificate becomes valid 10 days after vaccination with Yellow Fever Vaccine.
Laboratory Personnel: Laboratory personnel who handle virulent yellow fever virus or concentrated preparations of the yellow fever vaccine virus strains may be at risk of exposure by direct or indirect contact or by aerosols.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Prevention of Yellow fever •••••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Yellow Fever Vaccine is composed of two live, attenuated strains of yellow fever virus, 17D-204 and 17DD, which have been shown to elicit an immune response identical to that induced by wild-type infection Label. Vaccination with Yellow Fever vaccine is considered to be the most important and effective measure to protect against Yellow Fever, with protective immunity developing within 10 days after vaccination; in two separate clinical trials of Yellow Fever Vaccine, 90% of subjects seroconverted within 10 days after vaccination, and 100% of subjects seroconverted within 14 days Label.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Abacavir. Abatacept The risk or severity of infection can be increased when Yellow fever vaccine is combined with Abatacept. Acyclovir The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Acyclovir. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Yellow fever vaccine. Adefovir dipivoxil The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Adefovir dipivoxil. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Stamaril Injection, powder, lyophilized, for suspension; Kit 1000 [iU]/0.5mL Subcutaneous Sanofi Pasteur Inc. 2016-09-27 Not applicable US 
Yf-vax Injection, powder, lyophilized, for suspension 4.74 [PFU]/0.5mL Subcutaneous Sanofi Pasteur Inc. 1953-05-22 Not applicable US Yf-vax Powder, for solution 54954 PFU/0.5mL Subcutaneous Sanofi Pasteur Limited 1978-12-31 Not applicable Canada 
- Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Stamaril Yellow fever vaccine (1000 [iU]/0.5mL) Injection, powder, lyophilized, for suspension; Kit Subcutaneous Sanofi Pasteur Inc. 2016-09-27 Not applicable US
Categories
- ATC Codes
- J07BL01 — Yellow fever, live attenuated
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- PY4EET359T
- CAS number
- Not Available
References
- General References
- Ferreira CC, Campi-Azevedo AC, Peruhype-Magalhaes V, Costa-Pereira C, Albuquerque CP, Muniz LF, Yokoy de Souza T, Oliveira ACV, Martins-Filho OA, da Mota LMH: The 17D-204 and 17DD yellow fever vaccines: an overview of major similarities and subtle differences. Expert Rev Vaccines. 2018 Jan;17(1):79-90. doi: 10.1080/14760584.2018.1406800. Epub 2017 Nov 27. [Article]
- World Health Organization - Yellow Fever Fact Sheet [Link]
- World Health Organization - Yellow fever vaccination booster not needed [Link]
- CDC - Yellow Fever Symptoms and Treatment [Link]
- CDC - Yellow Fever Vaccine [Link]
- External Links
- PubChem Substance
- 347910911
- 89890
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Yellow_fever_vaccine
- FDA label
- Download (246 KB)
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample dataNot Available Completed Not Available Healthy Volunteers (HV) 1 somestatus stop reason just information to hide Not Available Completed Not Available Yellow Fever 1 somestatus stop reason just information to hide Not Available Completed Basic Science Healthy Volunteers (HV) 1 somestatus stop reason just information to hide Not Available Completed Prevention Granulomatosis With Polyangiitis / Juvenile Dermatomyositis (JDM) / Juvenile Idiopathic Arthritis (JIA) / Mixed Connective Tissue Disease (MCTD) / Myopathies, Inflammatory / Rheumatoid Arthritis / Sjögren's Syndrome (SS) / Spondyloarthritis (SpA) / Systemic Lupus / Systemic Sclerosis (SSc) / Takayasu Arteritis 1 somestatus stop reason just information to hide Not Available Enrolling by Invitation Prevention Yellow Fever 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, for suspension Intramuscular; Subcutaneous 1000 IU Injection, powder, lyophilized, for suspension; kit Subcutaneous 1000 [iU]/0.5mL Injection, powder, lyophilized, for solution Intramuscular; Subcutaneous Injection, powder, for suspension Subcutaneous 1000 IU/0.5ml Injection Intramuscular; Subcutaneous 1000 IU Injection, powder, lyophilized, for suspension Subcutaneous 4.74 [PFU]/0.5mL Powder, for solution Subcutaneous 54954 PFU/0.5mL - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at December 01, 2015 20:04 / Updated at November 01, 2023 04:05